Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, NY, USA.
Cell & Developmental Biology, SUNY Upstate Medical University, Syracuse, NY, USA.
Int J Radiat Biol. 2023;99(10):1570-1583. doi: 10.1080/09553002.2023.2188930. Epub 2023 Apr 20.
The oncogenic fusion protein EWS::FLI1 is an attractive therapeutic target in Ewing sarcoma (ES). Mithramycin A (MithA) is a potent and specific inhibitor of EWS::FLI1 that can selectively radiosensitize ES cells through transcriptional inhibition of DNA double-strand break (DSB) repair. Here, we evaluate temporal changes in cell cycle progression and apoptosis in ES cells treated with MithA and/or ionizing radiation (RTx), testing the hypothesis that combining MithA with ionizing radiation would synergistically impair cell cycle progression and enhance apoptotic elimination to a greater extent than either agent alone.
Four EWS::FLI1 ES cell lines TC-71, RD-ES, SK-ES-1, and A673, and one EWS::ERG cell line (CHLA-25) were exposed to 10nM MithA or vehicle and followed 24 h later by exposure to 2 Gy x-radiation or sham irradiation. Reactive oxygen species (ROS) activity was evaluated by cytometric assay, and assay of antioxidant gene expression by RT-qPCR. Cell cycle changes were evaluated by flow cytometry of nuclei stained with propidium iodide. Apoptosis was assessed by cytometric assessment of Caspase-3/7 activity and by immunoblotting of PARP-1 cleavage. Radiosensitization was evaluated by clonogenic survival assay. Proliferation (EdU) and apoptosis (TUNEL) were evaluated in SK-ES-1 xenograft tumors following pretreatment with 1 mg/kg MithA, followed 24 h later by a single 4 Gy fraction of x-radiation.
MithA-treated cells showed reduced levels of ROS, and were associated with increased expression of antioxidant genes , and . It nonetheless induced persistent G/G arrest and a progressive increase of the sub-G fraction, suggesting apoptotic degeneration. assays of Caspase-3/7 activity and immunoblotting of Caspase-3/7 dependent cleavage of PARP-1 indicated that apoptosis began as early as 24 h after MithA exposure, reducing clonogenic survival. Tumors from xenograft mice treated with either radiation alone, or in combination with MithA showed a significant reduction of tumor cell proliferation, while apoptosis was significantly increased in the group receiving the combination of MithA and RTx.
Taken together, our data show that the anti-proliferative and cytotoxic effects of MithA are the prominent components of radiosensitization of EWS::FLI1 ES, rather than the result of acutely enhanced ROS levels.
EWS::FLI1 致癌融合蛋白是尤文肉瘤(ES)的一个有吸引力的治疗靶点。米托蒽醌 A(MithA)是 EWS::FLI1 的一种有效且特异性抑制剂,可通过抑制 DNA 双链断裂(DSB)修复来选择性地放射增敏 ES 细胞。在这里,我们评估了用 MithA 和/或电离辐射(RTx)处理 ES 细胞后细胞周期进程和细胞凋亡的时间变化,检验了以下假设:与单独使用任一药物相比,联合使用 MithA 和电离辐射会协同地更严重地损害细胞周期进程并增强凋亡消除。
四种 EWS::FLI1 ES 细胞系 TC-71、RD-ES、SK-ES-1 和 A673,以及一种 EWS::ERG 细胞系(CHLA-25)暴露于 10nM MithA 或载体中,24 小时后再暴露于 2Gy X 射线或假照射。通过流式细胞术评估活性氧(ROS)活性,并通过 RT-qPCR 测定抗氧化基因表达。通过碘化丙啶染色细胞核的流式细胞术评估细胞周期变化。通过细胞色素 C 测定 Caspase-3/7 活性和 PARP-1 切割的免疫印迹评估细胞凋亡。通过集落形成存活测定评估放射增敏作用。在预处理 SK-ES-1 异种移植瘤中,用 1mg/kg MithA 处理,24 小时后再用单次 4GyX 射线照射,随后通过 EdU 评估增殖(EdU)和 TUNEL 评估凋亡。
用 MithA 处理的细胞显示出 ROS 水平降低,并且与抗氧化基因的表达增加有关, 和 。然而,它诱导持续的 G/G 期阻滞和亚 G 期分数的逐渐增加,提示凋亡退变。Caspase-3/7 活性测定和 Caspase-3/7 依赖性 PARP-1 切割的免疫印迹表明,凋亡早在 MithA 暴露 24 小时后就开始发生,从而降低了集落形成能力。单独接受辐射或联合 MithA 治疗的肿瘤小鼠的肿瘤细胞增殖显著减少,而联合 MithA 和 RTx 治疗组的细胞凋亡显著增加。
总的来说,我们的数据表明,MithA 的抗增殖和细胞毒性作用是 EWS::FLI1 ES 放射增敏的主要成分,而不是急性增强 ROS 水平的结果。